In China, For Global

An innovative and globally competitive

biopharmaceutical company with a whole-industry-chain layout.

In China, For Global

An innovative and globally competitive

biopharmaceutical company with a whole-industry-chain layout.

Original Innovation, Science Oriented

Globally-integrated R&D process

Technology system encompassing the entire lifecycle of antibodies

Innovation-driven Biopharma

China’s leading innovative biopharmaceutical company

Established in December, 2012

Therapeutic Area

  • Oncology

    JS001(PD-1), JS003 (PD-L1), JS004 (BTLA)

  • Autoimmune

    JS005 (IL-17A), UBP1211 (TNF-α), UBP1213 (BLyS)

  • Metabolic

    JS002 (PCSK9), JS103 (Uricase), JS008 (Undisclosed)

  • Neurological

    JS010 (CGRP)

  • Infectious

    JS016 (S protein), VV116 (RdRp), VV993 (3CL )

Therapeutic Area

  • Oncology
  • Autoimmune
  • Metabolic
  • Neurological
  • Infectious
Learn more

Our Milestones

News Center

  • Dec 11, 2022

    Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

    >SHANGHAI, China, December 10, 2022 (GLOBE NEWSWIRE) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the updated preliminary data from a Phase I study of tifcemalimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas in a poster at the 64th American Society of Hematology (ASH) Annual Meeting. Tifcemalimab is the world’s first-in-human anti-tumor anti-BTLA monoclonal antibody independently developed by the company.

    View details
  • Nov 24, 2022

    Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

    >HANGHAI, China, November 24, 2022 (GLOBE NEWSWIRE) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company has submitted a marketing authorization application (“MAA”) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) for toripalimab. The indications requested in the MAA are: 1) Toripalimab, in combination with cisplatin and gemcitabine, for the first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and

    View details
  • Nov 15, 2022

    Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab

    >SHANGHAI, China, November 15, 2022 (GLOBE NEWSWIRE) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (“EMA”) for toripalimab. The indications requested in the MAA are:

    View details
Join us

打造世界一流、值得信赖的生物源创药普惠患者

View details